Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's Disease. Journal of Alzheimer's disease : JAD Sabbagh, M. N., Schäuble, B., Anand, K., Richards, D., Murayama, S., Akatsu, H., Takao, M., Rowe, C. C., Masters, C. L., Barthel, H., Gertz, H., Peters, O., Rasgon, N., Jovalekic, A., Sabri, O., Schulz-Schaeffer, W. J., Seibyl, J. 2017; 56 (2): 441-446

Abstract

Of 57 individuals diagnosed with Alzheimer's disease (AD) in a phase III study, 13 (23%) had amyloid-ß (Aß) levels on postmortem histopathology that did not explain the dementia. Based on postmortem histopathology, a wide range of different non-AD conditions was identified, including frontotemporal dementia, hippocampal sclerosis, and dementia with Lewy bodies. Of the histopathologically Aß negative scored cases ante-mortem Florbetaben PET scans were classified as negative for Aß in 11 patients based on visual analysis and in all 12 quantifiable cases based on composite standardized uptake value ratios. Thus, florbetaben PET can assist physicians in the differential diagnosis of neurodegenerative disorders by reliably excluding Aß pathology.

View details for DOI 10.3233/JAD-160821

View details for PubMedID 27983552